(Q33925129)

English

A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

phase II clinical trial

0 references

darbepoetin alfa

0 references

1 reference

based on heuristic

inferred from title

author name string

Jason Gotlib

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Philip Lavori

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sylvia Quesada

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Richard S Stein

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Shahin Shahnia

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Peter L Greenberg

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

84

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

15-20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

5 July 2018

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

5 July 2018

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

5 July 2018

Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

5 July 2018

Serum erythropoietin concentrations in patients with myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

5 July 2018

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

29 October 2018

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

29 October 2018

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

29 October 2018

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

29 October 2018

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5524518

29 October 2018

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19006226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19006226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19006226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19006226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19006226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19006226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study]

1 reference

https://pubmed.ncbi.nlm.nih.gov/19006226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/AJH.21316

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33925129&oldid=1975285972"